Post

Christian Angermayer, the chairman of Germany-based biopharmaceutical company atai Life Sciences (ATAI) announced today that the firm would develop its own bitcoin treasury strategy.



“In an era of persistent inflation and volatile markets, I find myself asking an important question for biotech companies looking to preserve and optimize the capital they have: Could allocating a portion of treasury cash to bitcoin help preserve, optimize, and even extend a company’s runway and hence contribute to its success,” Angermayer wrote on Substack.

The company will initially invest $5 million in bitcoin, Angermayer said, while holding enough cash, short-term securities and public equity for operational expenses into 2027.
#TUT Price Rise
#Crypto ETFs Under Application
This page contains third-party content and does not constitute any advice, nor does it represent Gate's endorsement of such views. For details, please see disclaimer.
OWNOWN0.00%
BTCBTC-0.35%


Add a comment
Add a comment

Comment
sumon123
2025-05-28
Buy To Earn 💎
0
miss_1903
2025-03-21
First Review
HODL Tight 💪
0